Last reviewed · How we verify
Regadenoson infusion
At a glance
| Generic name | Regadenoson infusion |
|---|---|
| Sponsor | Christine Lau, MD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI (NA)
- Treat COVID-19 Patients With Regadenoson (PHASE1, PHASE2)
- Regadenoson R-T Perfusion Imaging Trial (PHASE1)
- Cardiac Magnetic Resonance Stress-perfusion Study in Patinets with Fontan Circulation
- A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT) (PHASE2)
- Regadenoson Real Time Perfusion Imaging Trial-Optison (PHASE3)
- Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System (EARLY_PHASE1)
- Microvascular Blood Flow in Sickle Cell Anemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regadenoson infusion CI brief — competitive landscape report
- Regadenoson infusion updates RSS · CI watch RSS
- Christine Lau, MD portfolio CI